Protein Science, Vol 6, Issue 9 1806-1824, Copyright © 1997 by Cold Spring Harbor Laboratory Press

ARTICLE

Crystal structures of bovine chymotrypsin and trypsin complexed to the inhibitor domain of Alzheimer's amyloid {beta}-protein precursor (APPI) and basic pancreatic trypsin inhibitor (BPTI): Engineering of inhibitors with altered specificities

A. J. SCHEIDIG, T. R. HYNES, L. A. PELLETIER, J. A. WELLS and A. A. KOSSIAKOFF
The first two authors contributed equally to the work. Present address: Max-Planck-Institut fur Moleculare Physiologie, Rheinlanddamm 201, 44026 Dortmund, Germany.

The crystal structures of the inhibitor domain of Alzheimer's amyloid {beta}-protein precursor (APPI) complexed to bovine chymotrypsin (C-APPI) and trypsin (T-APPI) and basic pancreatic trypsin inhibitor (BPTI) bound to chymotrypsin (C-BPTI) have been solved and analyzed at 2.1 A, 1.8 A, and 2.6 A resolution, respectively. APPI and BPTI belong to the Kunitz family of inhibitors, which is characterized by a distinctive tertiary fold with three conserved disulfide bonds. At the specificity-determining site of these inhibitors (P1), residue 15(I)(4) is an arginine in APPI and a lysine in BPTI, residue types that are counter to the chymotryptic hydrophobic specificity. In the chymotrypsin complexes, the Arg and Lys P1 side chains of the inhibitors adopt conformations that bend away from the bottom of the binding pocket to interact productively with elements of the binding pocket other than those observed for specificity-matched P1 side chains. The stereochemistry of the nucleophilic hydroxyl of Ser 195 in chymotrypsin relative to the scissile P1 bond of the inhibitors is identical to that observed for these groups in the trypsin-APPI complex, where Arg 15(I) is an optimal side chain for tryptic specificity. To further evaluate the diversity of sequences that can be accommodated by one of these inhibitors, APPI, we used phage display to randomly mutate residues 11, 13, 15, 17, and 19, which are major binding determinants. Inhibitor variants were selected that bound to either trypsin or chymotrypsin. As expected, trypsin specificity was principally directed by having a basic side chain at P1 (position 15); however, the P1 residues that were selected for chymotrypsin binding were His and Asn, rather than the expected large hydrophobic types. This can be rationalized by modeling these hydrophilic side chains to have similar H-bonding interactions to those observed in the structures of the described complexes. The specificity, or lack thereof, for the other individual subsites is discussed in the context of the ``allowed'' residues determined from a phage display mutagenesis selection experiment.
CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Y. A. Andreev, S. A. Kozlov, S. G. Koshelev, E. A. Ivanova, M. M. Monastyrnaya, E. P. Kozlovskaya, and E. V. Grishin Analgesic Compound from Sea Anemone Heteractis crispa Is the First Polypeptide Inhibitor of Vanilloid Receptor 1 (TRPV1) J. Biol. Chem., August 29, 2008; 283(35): 23914 - 23921. [Abstract] [Full Text] [PDF]

				H. Li, P. C. Chien Jr., M. Tuen, M. L. Visciano, S. Cohen, S. Blais, C.-F. Xu, H.-T. Zhang, and C. E. Hioe Identification of an N-Linked Glycosylation in the C4 Region of HIV-1 Envelope gp120 That Is Critical for Recognition of Neighboring CD4 T Cell Epitopes J. Immunol., March 15, 2008; 180(6): 4011 - 4021. [Abstract] [Full Text] [PDF]

				E. S. Radisky, J. M. Lee, C.-J. K. Lu, and D. E. Koshland Jr. Insights into the serine protease mechanism from atomic resolution structures of trypsin reaction intermediates PNAS, May 2, 2006; 103(18): 6835 - 6840. [Abstract] [Full Text] [PDF]

				D. Navaneetham, L. Jin, P. Pandey, J. E. Strickler, R. E. Babine, S. S. Abdel-Meguid, and P. N. Walsh Structural and Mutational Analyses of the Molecular Interactions between the Catalytic Domain of Factor XIa and the Kunitz Protease Inhibitor Domain of Protease Nexin 2 J. Biol. Chem., October 28, 2005; 280(43): 36165 - 36175. [Abstract] [Full Text] [PDF]

				A. E. Schmidt, H. S. Chand, D. Cascio, W. Kisiel, and S. P. Bajaj Crystal Structure of Kunitz Domain 1 (KD1) of Tissue Factor Pathway Inhibitor-2 in Complex with Trypsin: IMPLICATIONS FOR KD1 SPECIFICITY OF INHIBITION J. Biol. Chem., July 29, 2005; 280(30): 27832 - 27838. [Abstract] [Full Text] [PDF]

				A. E. Schmidt, T. Ogawa, D. Gailani, and S. P. Bajaj Structural Role of Gly193 in Serine Proteases: INVESTIGATIONS OF A G555E (GLY193 IN CHYMOTRYPSIN) MUTANT OF BLOOD COAGULATION FACTOR XI J. Biol. Chem., July 9, 2004; 279(28): 29485 - 29492. [Abstract] [Full Text] [PDF]

				H. S. Chand, A. E. Schmidt, S. P. Bajaj, and W. Kisiel Structure-Function Analysis of the Reactive Site in the First Kunitz-type Domain of Human Tissue Factor Pathway Inhibitor-2 J. Biol. Chem., April 23, 2004; 279(17): 17500 - 17507. [Abstract] [Full Text] [PDF]

				O. Buczek, K. Koscielska-Kasprzak, D. Krowarsch, M. Dadlez, and J. Otlewski Analysis of serine proteinase-inhibitor interaction by alanine shaving Protein Sci., April 1, 2002; 11(4): 806 - 819. [Abstract] [Full Text] [PDF]

				A. Roussel, M. Mathieu, A. Dobbs, B. Luu, C. Cambillau, and C. Kellenberger Complexation of Two Proteic Insect Inhibitors to the Active Site of Chymotrypsin Suggests Decoupled Roles for Binding and Selectivity J. Biol. Chem., October 12, 2001; 276(42): 38893 - 38898. [Abstract] [Full Text] [PDF]

				S. Chakraborty, S. Bhattacharya, S. Ghosh, A.K. Bera, U. Haldar, A.K. Pal, B.P. Mukhopadhyay, and A. Banerjee Structural and interactional homology of clinically potential trypsin inhibitors: molecular modelling of Cucurbitaceae family peptides using the X-ray structure of MCTI-II Protein Eng. Des. Sel., August 1, 2000; 13(8): 551 - 555. [Abstract] [Full Text] [PDF]

				C. Chen, C.-H. Hsu, N.-Y. Su, Y.-C. Lin, S.-H. Chiou, and S.-H. Wu Solution Structure of a Kunitz-type Chymotrypsin Inhibitor Isolated from the Elapid Snake Bungarus fasciatus J. Biol. Chem., November 21, 2001; 276(48): 45079 - 45087. [Abstract] [Full Text] [PDF]